Abstract Alzheimer's disease (AD), the most common form of dementia, remains challenging
to understand and treat despite decades of research and clinical investigation. This might be …

Discovery and development of clinically useful biomarkers for Alzheimer's disease (AD) and
related dementias have been the focus of recent research efforts. While cerebrospinal fluid …

Alzheimer's disease (AD) is a neurodegenerative disorder associated with a severe loss in
thinking, learning, and memory functions of the brain. To date, no specific treatment has …

Electrode miniaturization has profoundly revolutionized the field of electrochemical sensing,
opening up unprecedented opportunities for probing biological events with a high spatial …

The development of blood-based biomarkers of Alzheimer's disease (AD) pathology as tools
for screening the general population, and as the first step in a multistep process to determine …

Highlights•Protein biomarkers in cerebrospinal fluid now define Alzheimer's disease
(AD).•New ultrasensitive techniques have enabled promising replication in blood.•This …

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder and affects more
than 10% of the population aged over 65 worldwide. Despite considerable global efforts, AD …

Background Visinin-like protein 1 (VILIP-1) belongs to the group of emerging biomarkers
with the potential to support the early diagnosis of Alzheimer's disease (AD). However …

Progressive amyloid-β (Aβ) fibrillar aggregates have long been considered as the
pathogenesis of Alzheimer's disease (AD). Biocompatible and stable cysteine–Aβ peptide …

Because of the brain's complexity, develo** effective treatments for neurological disorders
is a formidable challenge. Research efforts to this end are advancing as in vitro systems …